𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of advanced untreated Hodgkin's disease with SCAB—an alternative to MOPP

✍ Scribed by Charles H. Diggs; Peter H. Wiernik; John C. Sutherland


Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
407 KB
Volume
47
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Treatment of MOPP-refractory Hodgkin-s d
✍ Lawrence H. Einhorn; Stephen D. Williams; Eugene E. Stevens; William H. Bond; Li 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV d

Treatment of advanced Hodgkin's disease
✍ John G. Krikorian; Carol S. Portlock; Dr. Saul A. Rosenberg 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 2 views

twenty-seven patients with advanced Hodgkin's disease who failed MOPP (nitrogen mustard, vincristine, procarbazine and prednisone) were treated with adriamycin, bleomycin, vinblastine, and imidazole carboxamide, (ABVD). Complete response (CR) was achieved in 22% of patients and partial response was

Treatment of Hodgkin's disease in childr
✍ van den Berg, Henk; Stuve, Wouter; Behrendt, Henk 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

Since the introduction of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy, children with Hodgkin's disease (HD) have been treated with chemotherapy alone. The occurrence of side effects related to irradiation (especially secondary solid tumors) is less likely to occur.

Hybrid chemotherapy consisting of cyclop
✍ Silvia Montoto; Mireia Camós; Armando López-Guillermo; Francesc Bosch; Francisco 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## BACKGROUND. Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD). Although a prolonged complete response (CR) is achieved in up to 70 -80% of patients, long term complications, such as secondary leukemia, are of concern. C